Aktis Oncology, a Phase 1 biotech developing targeted radiopharmaceuticals to treat solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Aktis Oncology is a clinical-stage oncology company developing alpha-emitting radiopharmaceuticals against prevalent solid tumors. Its pipeline features Ac-AKY-1189 for Nectin-4-expressing cancers, now enrolling about 150 patients in a multi-site US Phase 1b trial with preliminary results expected in the first quarter of 2027, and Ac-AKY-2519 targeting B7-H3-expressing tumors with an IND filing planned for 2026. It also manages multiple domestic and international isotope supply partnerships, invests in an internal cGMP facility set to be operational in 2026, and holds a discovery collaboration for additional miniprotein radioconjugate programs.
The Boston, MA-based company was founded in 2020 and booked $6 million in revenue for the 12 months ended September 30, 2025. It plans to list on the Nasdaq under the symbol AKTS. J.P. Morgan, BofA Securities, Leerink Partners, and TD Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.